Dec 2014 – Dec 2018 / ACTELION PHARMACEUTICALS
Responsible for developing an ultra-rare neurodegenerative disease area by collaborating with KOLs and PAGs on innovative clinical projects (IISs), digital clinical support tools, impactful scientific communication/education, and disease awareness campaigns.
